Autologous Stem Cell Transplantation in Myelodysplastic Syndromes

Seminars in Hematology

Volumn 44, Issue 4, 2007, Pages 274-277

  de Witte, Theo ^a   Suciu, Stefan ^b   Brand, Ronald ^c   Muus, Petra ^a   Kröger, Nicolaus ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b European Organisation of Research and Treatment of Cancer   (Belgium)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CYTOGENETICS; ELDERLY CARE; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HLA SYSTEM; HODGKIN DISEASE; HUMAN; LONG TERM CARE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RISK ASSESSMENT; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 35349014739     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.08.006     Document Type: Article

References (29)

1. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., and Machin D. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59 (1985) 425-433
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
3. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
4. Maes B., Meeus P., Michaux L., et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol 10 (1999) 825-829
5. Harris N.L., Jaffe E.S., Diebold J., et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J 1 (2000) 53-66
6. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000) 620-630
7. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
8. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
9. Oosterveld M., Suciu S., Verhoef G., et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17 (2003) 859-868
10. Oosterveld M., Muus P., Suciu S., et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16 (2002) 1615-1621
11. de Witte T., van Biezen B.A., Hermans J., et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90 (1997) 3853-3857
12. Kroger N., Brand R., van Biezen A., et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 37 (2006) 183-189
13. Wattel E., Solary E., Leleu X., et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia 13 (1999) 524-529
14. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326-2331
15. Ducastelle S., Ades L., Gardin C., et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica 91 (2006) 373-376
16. Pedersen-Bjergaard J., Specht L., Larsen S.O., et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 2 (1987) 83-88
17. Rubin C.M., Arthur D.C., Woods W.G., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 78 (1991) 2982-2988
18. Pedersen-Bjergaard J., Philip P., Larsen S.O., et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7 (1993) 1975-1986
19. Ballen K.K., and Antin J.H. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am 7 (1993) 477-493
20. Kantarjian H.M., Estey E.H., and Keating M.J. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 7 (1993) 81-107
21. Quesnel B., Kantarjian H., Bjergaard J.P., et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature. J Clin Oncol 11 (1993) 2370-2379
22. Yakoub-Agha I., de la Salmonière P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-Report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18 (2000) 963-971
23. Delforge M., Demuynck H., Vandenberghe P., et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86 (1995) 3660-3667
24. Demuynck H., Delforge M., Verhoef G.E., et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92 (1996) 351-359
25. de Witte T.M., Hagemeijer A., Suciu S., et al. Allogeneic (Allo-) or autologous (Auto-) peripheral blood stem cell transplantation (SCT) randomized versus a second intensive consolidation course in patients with bad prognosis myelodysplastic syndromes and acute myelogenous leukemia following MDS of more than 6 months duration: The final analysis of a joint study (Criant) of the EORTC, EBMT, SAKK, HOVON, and GIMEMA Leukemia groups. Blood 106 (2005) 794 (abstr)
26. Span L.F., and de Witte T.M. Biology of stem and myeloid progenitor cells in myelodysplastic syndromes. Cancer Treat Res 108 (2001) 45-63
27. Carella A.M., Dejana A., Lerma E., et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 95 (1996) 127-130
28. de Witte T, Brand R, van Biezen, et al: Peripheral stem cells are the preferred souce of stem cells for autologous stem cell transplantation (ASCT) of young patients with MDS or AML following MDS: An analysis of the chronic leukemia working party of the European Blood and Marrow Transplantation Group (EBMT). Blood 97:848a, (abstr 3525)
29. de Witte T., Brand R., van Biezen A., et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 91 (2006) 750-756